More MS news articles for April 2001

The Immune Response Corporation Granted U.S. Patent for the Use of Antibodies To Target T Cell Receptors to Treat Rheumatoid Arthritis

http://finance.individual.com/display_news.asp?doc_id=PR20010426LATH062&page=news

Thursday April 26  6:57am
Source: PR Newswire

CARLSBAD, Calif., April 26 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it was awarded United States Patent Number 6,221,352 that covers claims relating to the use of antibodies to target specific T Cell Receptors (TCRs) to treat rheumatoid arthritis. Specifically, the new patent covers the administration of monoclonal antibodies, alone and/or coupled to cytotoxic or cytostatic agents, that selectively bind to and prevent the proliferation of T Cells that express either Vbeta 14 or Vbeta 17 TCRs. These Vbeta 14 and Vbeta 17 T Cells serve as good targets for treating rheumatoid arthritis because they are among the over-expressed pathogenic T Cells thought to cause the disease. The Company believes that selectively targeting these "fingerprint" TCRs may help reduce the population of pathogenic T Cells and prevent further tissue damage in people suffering from rheumatoid arthritis.

"Approaches utilizing monoclonal antibodies are emerging in the marketplace as new options for treating human diseases, including autoimmune diseases such as rheumatoid arthritis," said Richard M. Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. "This patent allows us to utilize antibodies, either alone or coupled to chemotherapeutic or radioactive moieties, to target pathogenic T Cells for the treatment of rheumatoid arthritis. This is a valuable extension of our core technology on TCRs as therapeutic targets in autoimmune disease."

On March 30, 2001, the Company announced the issuance of U.S. Patent Number 6,207,645, which covers vaccination of individuals with rheumatoid arthritis using DNA vaccines designed to synthesize the key Vbeta TCR peptides. The Company also announced on August 9, 2000, that it was issued U.S. Patent Number 6,090,387 for vaccinating individuals with rheumatoid arthritis using the specific Vbeta TCR peptides.

The Immune Response Corporation's Vbeta TCR peptide vaccine, RAVAX(TM), has completed two Phase II clinical trials, exhibiting safety and a statistically significant treatment effect in individuals with rheumatoid arthritis. The Company has also carried out clinical trials using its core TCR peptide technology towards the development of investigational immune-based therapies to treat other autoimmune diseases, including multiple sclerosis and psoriasis.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

NOTE: News releases are available through PR Newswire Company News On- Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether preclinical data can be replicated in clinical trials, whether if initiated clinical trials will be successfully concluded and whether a preventative vaccine will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2000. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Source: The Immune Response Corporation
Contact: investors, Kathy Lane, 760-771-2236, or media, Laura Hansen, Ph.D., 858-860-0266, both of The Immune Response Corporation